NCT05424978 Application of Standardized Green Channel Treatment System for Ischemic Stroke in Xi 'an
| NCT ID | NCT05424978 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xi'an No.3 Hospital |
| Condition | Acute Ischemic Stroke |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,600 participants |
| Start Date | 2022-06-01 |
| Primary Completion | 2025-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,600 participants in total. It began in 2022-06-01 with a primary completion date of 2025-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Objective: To observe the practical application of the standardized green channel treatment system for stroke in Xi 'an in the real world. Methods: Clinical data and information of patients with acute ischemic stroke who received standardized green channel treatment for stroke were collected, and a multicenter observational clinical study was carried out in the real world to evaluate the prognosis, mortality, incidence of asymptomatic and symptomatic cerebral hemorrhage, incidence of pneumonia, and recurrence rate of stroke after 90 days.
Eligibility Criteria
Inclusion Criteria: * 18 years old; * Consistent with the diagnosis of acute ischemic stroke; * 24 hours from onset to enrollment; * Informed consent Exclusion Criteria: * Patients who refuse to receive intravenous thrombolysis or intravascular intervention (including intravascular mechanical thrombolysis and arterial thrombolysis); * Stroke patients caused by brain tumor, brain trauma and blood diseases; * Those with a history of stroke and sequelae affecting the outcome assessment, namely, mRS 2 points before the onset of this stroke; * Combined with claudication osteoarthritis rheumatoid arthritis gout arthritis and other limb dysfunction and affect the neurological function examination; * Patients with severe hepatic and renal insufficiency (Note: Hepatic insufficiency refers to ALT or AST values greater than 2 times the upper normal limit; Renal insufficiency refers to blood creatinine value greater than 2 times the normal upper limit); * Suffering from other serious life-threatening diseases with an expected survival time of less than 3 months; * Other diseases that limit neurological function evaluation or affect patient follow-up; * A woman planning to be pregnant or breastfeeding; * Currently participating in other clinical trials; * Refuse to participate in the registration of investigators
Contact & Investigator
Ye Tian, Doctor
STUDY DIRECTOR
The dean
Frequently Asked Questions
Who can join the NCT05424978 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Acute Ischemic Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05424978 currently recruiting?
Yes, NCT05424978 is actively recruiting participants. Contact the research team at changmingze191@163.com for enrollment information.
Where is the NCT05424978 trial being conducted?
This trial is being conducted at Xi'an, China.
Who is sponsoring the NCT05424978 clinical trial?
NCT05424978 is sponsored by Xi'an No.3 Hospital. The principal investigator is Ye Tian, Doctor at The dean. The trial plans to enroll 3,600 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.